TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Daratumumab
Drug Type Antibody
TTD ID D0RV4P
Toxicity Organism Test Type Route(Dose)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 892
Ref_1
Pair Name Tretinoin, Daratumumab
Partner Name All-trans-retinoic acid
Disease Info [ICD-11: 2A60.Z] Acute myeloid leukemia Investigative
Gene Regulation Up-regulation Expression NOTCH1 hsa4851
In Vitro Model MV4-11 Childhood acute monocytic leukemia Homo sapiens (Human) CVCL_0064
OCI-AML-3 Adult acute myeloid leukemia Homo sapiens (Human) CVCL_1844
MOLM-13 Adult acute myeloid leukemia Homo sapiens (Human) CVCL_2119
U-937 Adult acute monocytic leukemia Homo sapiens (Human) CVCL_0007
In Vivo Model For the leukemic model, 3.0×10⁵ spleen cells from MV4-11-engrafted mice were injected intravenously into 75 NSG mice.
Result These results suggest that, although ATRA does not induce differentiation of non-APL, it may be effective as a therapy in conjunction with DARA.
03. Reference
No. Title Href
1 Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol. 2018 Jul 24;30(8):375-383. doi: 10.1093/intimm/dxy040. Click
It has been 198266 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP